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Outcomes of non-infectious Paediatric
uveitis in the era of biologic therapy
Megan Cann1, Athimalaipet V. Ramanan1,2*†, Andrew Crawford3,4, Andrew D. Dick1,2,5,6, Sarah L. N. Clarke1,4,
Fatima Rashed2 and Catherine M. Guly1†
Abstract
Background: There is a paucity of data on the ocular outcomes in paediatric non-infectious uveitis since the
introduction of the biologic agents. The purpose of this study was to outline the clinical characteristics of children
with non-infectious uveitis and determine the visual outcomes and ocular complication rates in the modern era.
Methods: Children with non-infectious uveitis from January 2011 to December 2015 were identified. Data was
collected at baseline, 1, 3, 5, and 10 years post diagnosis. The incidence rates of visual impairment, structural ocular
complications and surgical intervention were calculated. Using logistic regression the association between various
baseline characteristics and later visual impairment was investigated.
Results: Of the 166 children, 60.2% (n = 100) had a systemic disease association. 72.9% (n = 121) children received
methotrexate, 58 children progressed to a biologic. The incidence rates of visual acuity loss to > 0.3 LogMAR (6/12)
and to ≥1.0 LogMAR (6/60) were 0.05/Eye Year (EY) and 0.01/EY, respectively. Visual outcomes in the Juvenile
Idiopathic Arthritis associated Uveitis (JIA-U) and Idiopathic Uveitis cohorts were not statistically significant. Of the
293 affected eyes, posterior synechiae was the predominant complication on presentation, while cataract had the
highest incidence rate (0.05/EY). On direct comparison, children with JIA-U were statistically significantly more likely
to develop glaucoma while children with Idiopathic Uveitis were statistically significantly more likely to develop
macular oedema.
Conclusion: One third of children received a biological therapy, reflecting increasing utilisation and importance of
biological agents in the management of inflammatory conditions. Rates of visual impairment and ocular
complications are an improvement on previously published data.
Keywords: Uveitis, Biologics, Paediatrics, Visual outcomes
Background
Uveitis is rare in the paediatric population, with an esti-
mated incidence of 4.3 per 100,000 and a prevalence of
27.9 per 100,000 [1, 2] but there is a high rate of chronic
disease [3]. Non-infectious uveitis accounts for between
69 and 95% of childhood uveitis [4–7]. Juvenile Idio-
pathic Arthritis associated Uveitis (JIA-U) makes up 41–
47% of cases but equally in 28–51% of children no cause
is found [7–9]. Ocular complications including cataract,
glaucoma and macular oedema are reported in up to
76% of all cases of paediatric uveitis [4]. Visual impair-
ment is common but reporting is variable making com-
parisons difficult. Using incidence rates of visual
impairment, visual loss in children with JIA-U has been
reported at 0.10/EY [10]. Other studies have reported
overall rates of visual impairment in at least one affected
eye between 17 and 37% and 5 year rates of 36.36 and
15.1% for visual acuity worse then 20/50 and 20/200 re-
spectively [3, 4, 8].
Topical corticosteroids carry a risk of cataract and glau-
coma [11] and increasingly early use of immunosuppressive
agents is advocated in chronic non-infectious uveitis to re-
duce the risk of visual loss [12, 13]. Methotrexate is the
most commonly prescribed immunosuppressive therapy in
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paediatric uveitis [13], but 27–48% children do not achieve
control of inflammation and 20% experience adverse events
[14–16]. Use of infliximab in the management of refractory
paediatric uveitis was first reported in 2005 [17]. The fol-
lowing year a small case series of adalimumab for paediatric
uveitis was published [18]. Adalimumab was licenced for
adult and paediatric non-infectious uveitis in 2016 and
2017 respectively following successful outcome of rando-
mised controlled trials (RCTs) [19, 20].
There is a paucity of data on longer term outcomes of
paediatric uveitis (including JIA-U) in the era of biologic
treatment. The aim of this retrospective study is to de-
termine the visual outcomes and ocular complications of
children attending a tertiary service covering the
South-West of England and the South of Wales (ap-
proximate population of 5.5 million).
Methods
Patient identification
Bristol Eye Hospital Databases were reviewed to identify
all patients with uveitis. Children were included if they
had been diagnosed with non-infectious uveitis prior to
the age of 16 years and been managed at the Bristol Eye
Hospital between January 2011and December 2015.
Children referred to the service were either resident in
Bristol and referred from local medical services (primary
referrals) or lived outside Bristol and were referred from
surrounding ophthalmology services(tertiary referrals).
Data collection
Data was collected retrospectively at standard time inter-
vals; diagnosis, and 1, 3, 5 and 10 years. The appointment
closest to the time interval was selected for analysis.
Demographic data included age at diagnosis, gender and
ethnicity. Clinical uveitis details included aetiology, lateral-
ity, anatomical location using Standardization of Uveitis
Nomenclature (SUN) criteria [21] and structural compli-
cations. Elevated intraocular pressure (IOP) was defined
as > 21 mmHg and hypotony as < 5 mmHg. Pharmaco-
logical and surgical treatments were documented. Visual
acuity was recorded in logMAR. LogMAR is the logarith-
mic representation of visual acuity. It is the accepted
standard of representing visual acuity in research as it is
recognised to be more reliable, discriminative and repeat-
able when compared to the classic Snellen’s chart [22].
Visual impairment was stratified by severity as logMAR >
0.3 (worse than 6/12) or ≥ 1.0 (6/60 or worse) [21].
Statistical analysis
The incidence rates of visual impairment and structural
ocular complications were calculated for the whole
population, and for the JIA-U and idiopathic uveitis co-
horts. Not all patients contributed at all time points. In-
cidence rates were calculated per at risk eye year using
longitudinal data analysis to account for variable length
of follow up [23]. Year of complication onset was not re-
corded for 20 out of a total of 247 events (band keratop-
athy n = 5, cataracts n = 8, glaucoma n = 3, posterior
synechiae n = 1, elevated IOP n = 3). A year of onset of
4 years was used for these events as this was the nearest
whole year to the study cohort’s mean years of follow-up
(range from 3.8 to 4.5 years). The association between
various baseline characteristics and later visual impair-
ment was investigated using logistic regression (crude
and adjusting for age and sex). Analyses allowed for
intragroup correlation between eyes in patients with bi-
lateral events. Analyses were performed using Stata 14
statistical software (Stata Corp, College Station, Texas).
Data collection was approved by the hospital trust and
ethics committee approval was not required.
Results
Patient demographics and clinical characteristics of the
166 patients included in the study are outlined in Table 1.
Of the 50 children with unilateral uveitis on presentation,
11 progressed to bilateral disease. A total of 293 affected
eyes were included in the study. Baseline information was
available for 234 eyes in total. 60.2% of patients had an
underlying systemic disease association (Fig. 1). JIA was
the primary associated systemic disease, however Tubu-
lointerstitial Nephritis and Uveitis (TINU; 4 patients, 6
eyes), Blau (3 patients; 6 eyes), Behcet (1 patient; 1 eye)
and undifferentiated inflammatory disease (1 patient; 2
eyes) was also present. Anterior uveitis was the most com-
mon form of uveitis occurring in 125 patients (75.3%). In
JIA 89 out of 91 patients (97.8%) had anterior uveitis. Un-
fortunately time to diagnosis data was not available for the
cohort. Of the 93 tertiary referral patients (i.e. referred
from surrounding ophthalmology services for subspecialist
opinion); 64.5, 8.6, 10.8, 6.5 and 9.7% were seen at the ter-
tiary centre within 3 months, 1 year, 3 years, 5 years and
10 years of diagnosis respectively.
Medications are recorded in Table 1. The first line sys-
temic immunosuppressive agent for all children was
methotrexate. Of the 166 patients, 39 (23.5%) children
received additional conventional DMARD therapy; either
as monotherapy or in combination with Methotrexate
(20/91 JIA patients, 17/66 idiopathic uveitis patients and
2/9 patients with other systemic diseases). 58 children
(34.4%) received a biologic agent and 14 children (8.4%)
required ≥2 biologics over the follow up period. No child
received a biologic agent at baseline. Biologics were
more likely to be delivered to children with JIA-U (43
children; 47.3%) than those with idiopathic uveitis (10
children; 15.2%). 7 (10.6%) children with idiopathic uve-
itis did not require treatment (p = < 0.001).
A total of 678 person years and 1216 eye years (EY) of
follow up were available. For the total population the
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Table 1 Patient Demographic and Clinical Characteristics
Cohort (%) JIA (%) Other Associated Systemic Disease(%) Idiopathic (%)
No. of Patients 166 91 (54.8) 9 (5.4) 66 (39.8)
Female 99 (59.6) 62 (68.1) 2 (22.2) 35 (53)
Age at diagnosis
Average 8.03y 5.9y 10.5y 10.7y
Median 7y 5y 12y 11y
Referral type
Tertiary 93 (56) 56 (61.5) 6 (66.7) 31 (47)
Ethnicity
Caucasian 128 (77.1) 73(80.2) 6 (66.7) 49 (74.2)
Asian 8 (4.8) 2 (2.2) 2 (22.2) 4 (6)
African 1 (0.6) 0 0 1 (1.5)
Other 7 (4.2) 2 (2.2) 1 (11.1) 4 (6)
Unknown 22 (13.3) 14 (15.4) 0 8 (12.1)
Laterality on presentation
Bilateral 116 (69.9) 62 (68.1) 5 (55.6) 49 (74.2)
Anatomic Localisation
Anterior 125 (75.3) 89 (97.8) 5 (55.6) 31 (47)
Intermediate 29 (17.5) 0 1 (11.1) 28 (42.4)
Posterior 1 (0.6) 0 0 1 (1.5)
Panuveitis 11 (6.6) 2 (2.2) 3 (33.3) 6 (9.1)
Visual Impairment at baseline (per eye)
> 0.3logMAR 43 (18.4) 22 (18.6) 3 (27.3) 18 (17.1)
≥ 1.0 logMAR 10 (4.3) 7 (5.9) 0 3 (2.9)
Medication use over study
Corticosteroids
Topical CS 155 (93.4) 91 (100) 8 (88.9) 56 (84.8)
Systemic CS 58 (34.9) 28 (30.8) 7 (77.8) 23 (34.8)
Peri/Intraocular 12 (7.2) 6 (6.6) 3 (33.3) 6 (9.1)
Steroids
Conventional DMARD 121 (72.9) 82 (90.1) 6 (66.7) 33 (50)
Methotrexate 121 (72.9) 82 (90.1) 6 (66.7) 33 (50)
Only Methotrexate 47 (28.3%) 35 (38.5) 1 (11.1) 11 (16.7)
Mycophenolate 36 (21.7) 19 (20.9) 2 (22.2) 15 (22.7)
mofetil
Tacrolimus 6 (3.6) 3 (3.3) 0 3 (4.5)
Ciclosporin 3 (1.8) 2 (2.2) 0 1 (1.5)
Biologics 58 (34.9) 43 (47.3) 5 (55.6) 10 (15.2)
Adalimumab 52 (31.3) 38 (41.8) 5 (55.6) 9 (13.6)
Infliximab 19 (11.4) 14 (15.4) 4 (44.4) 1 (1.5)
Abatacept 3 (1.8) 3 (1.8) 0 0
Tocilizumab 2 (1.2) 2 (1.2) 0 0
At presentation 118 eyes JIA, 11 other associated systemic diseases and 105 idiopathic
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median duration of follow up was 5 years. Children with
JIA-U had a longer duration of follow up when compared
to children with idiopathic uveitis (median 5 years vs
3 years). Availability of follow up data is outlined in Fig. 1.
34 children contributed only 1 visit; the majority of these
children (21 children) were tertiary referrals seen at least 1
year post diagnosis. The median number of evaluation visits
per patient was 3. Rates of complications at presentation
and incidence rates of newly diagnosed complications are
summarised in Table 2. The rates of visual acuity loss over
the period of observation to > 0.3 LogMAR and to ≥1.0
LogMAR among affected eyes were 0.05/EY and 0.01/EY,
respectively. At presentation 81/234 eyes (34.6%) had at
least one ocular uveitis associated complication, of which
posterior synechiae was the most common (43 eyes; 18.4%).
The rate of newly diagnosed band keratopathy and poster-
ior synchiae was 0.02/EY. Children with JIA-U were more
likely to develop raised IOP (p = 0.05) and glaucoma (p =
0.002) when compared to children with idiopathic uveitis,
while children with idiopathic uveitis were more likely to
developed macular oedema (p = 0.01) over the period of fol-
low up. Cataract was the frequent complication to occur
over the follow up period with an incidence rate of 0.05/
EY.Three eyes (3 children) had amblyopia. All three eyes
had visual impairment, 2 eyes had ≥1.0 logMAR and one
had > 0.3logMAR. There was no statistical difference be-
tween the rate of visual impairment between children with
anterior uveitis versus children with intermediate uveitis.
The incidence rate of visual impairment > 0.3 logMAR for
anterior uveitis was 0.04/EY (CI95% 0.03–0.06) compared
to 0.05/EY (CI95% 0.02–0.11) for children with intermedi-
ate uveitis (p = 0.80). No child with intermediate uveitis de-
veloped a visual impairment of ≥1.0logMAR over the study
period whereas the incidence in children with anterior uve-
itis was 0.01/EY (CI95% 0.01–0.02) (p = 0.13). Additionally,
there was no significant difference between rates of visual
impairment in those children with JIA-U anterior uveitis
and non-JIA-U anterior uveitis. Children with JIA-U
Fig. 1 Data Available at Standard Time Intervals Detailed information of the number of patients and affected eyes per aetiology at baseline,
1 year, 3 years, 5 years and 10 years post diagnosis
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anterior uveitis had an incidence rate of visual im-
pairment > 0.3logMAR of 0.05/EY (CI95% 0.03–0.07)
compared to 0.02/EY (CI95% 0.01–0.07) in the
non-JIA-U anterior group (p = 0.19). The rate of vis-
ual impairment ≥1.0logMAR between the JIA-U an-
terior uveitis and the non-JIA-U anterior uveitis
cohort was 0.01/EY (CI95% 0.00–0.05) and 0.01/EY
(CI95% 0.01–0.03) respectively (p = 0.5).
Surgical procedures were required in 38 eyes and in
some cases one eye received multiple procedures.
Cataract extraction was the most common procedure,
performed in 24 eyes (0.9% within 3 months of pres-
entation; Incidence rate 0.02/EY). 20 eyes received an
intraocular lens implant and 3 remained aphakic.
Lens insertion data was not available for 1 eye. Tra-
beculectomy was required in 11 eyes (0.01/EY) and
vitrectomy in 10 eyes (0.9% within 3 months of pres-
entation; 0.01/EY). Indication for vitrectomy is as fol-
lows; uncontrolled inflammation despite aggressive
therapy (3 eyes), vitreal debris (3 eyes), cyclitic mem-
brane (1 eye) and undocumented reasons (3 eyes) Pa-
tients with JIA were more likely to require cataract
removal and trabeculectomy than those with idio-
pathic uveitis (p = 0.04 and p = 0.01 respectively) over
the period of follow up. Two children required an
enucleation at 5 and 10 years follow up. Both eyes
had severe sight loss and required removal due to
chronic pain.
Using logistic regression, demographic and clinical
characteristics on presentation were analysed to deter-
mine whether they were predictive of visual impairment.
These characteristics are detailed in Table 3. Tertiary re-
ferral patients were statistically more likely to develop a
visual impairment of logMAR > 0.3 (p = 0.03) and ≥ 1.0
(p = 0.05). The presence of posterior synechiae at presen-
tation was also a risk factor for visual impairment ≥1.0
logMAR (p = 0.01).
Discussion
We report a large cohort of children with
non-infectious uveitis managed in a UK tertiary unit.
Use of systemic immunosuppression was high with
72.9% of children receiving methotrexate and 34.9%
receiving a biologic agent. The recent publication of
the SYCAMORE trial [20] has supported the efficacy
of rapid escalation to biologics in the management of
children with JIA-U refractory to conventional im-
munosuppressive therapy.
Despite published evidence that up to 73% of children
experience improvement in intraocular inflammation
with methotrexate [14], in this population methotrexate
refractory disease was common. Of the 121 children
Table 3 Patient Risk Factors at Baseline for Visual Impairment
Risk of Visual Impairment > 0.3logMAR Risk of Visual Impairment ≥1.0 logMAR
OR (95%CI) p (0.05) p (0.05)
Demographics
Age at uveitis diagnosis 0.97 (0.87–1.08) 0.56 1.02 (0.88–1.19) 0.76
Bilateral Disease 1.23 (0.46–3.34) 0.68 0.45 (0.12–1.65) 0.23
Female 1.43 (0.61–3.36) 0.41 1.24 (0.38–4.12) 0.72
Tertiary Referral 2.71 (1.12–6.56) 0.03 4.59 (0.98–21.47) 0.05
Aetiology
JIA 2.05 (0.88–4.77) 0.10 2.15 (0.62–7.43) 0.23
Idiopathic 0.54 (0.23–1.29) 0.16 0.23 (0.05–1.09) 0.07
Uveitis Characteristics
Anterior Uveitis 0.89 (0.37–2.14) 0.80 0.89 (0.26–3.07) 0.85
Bilateral Disease 1.23 (0.46–3.34) 0.68 0.45 (0.12–1.65) 0.23
Complications at Baseline
Band keratopathy 1.24 (0.24–6.37) 0.80 1.12 (0.15–8.53) 0.92
Cataracts 1.43 (0.29–6.99) 0.66 5.16 (0.91–29.23) 0.06
Posterior synechiae 0.84 (0.26–2.71) 0.77 4.91 (1.38–17.39) 0.01
Elevated IOP 0.35 (0.05–2.51) 0.29 1.00
Macular oedema 1.09 (0.12–10.07) 0.94 1.00
Hypotony 2.20 (0.19–25.31) 0.53 7.08 (0.64–78.00) 0.11
Optic disc swelling 0.98 (0.29–3.30) 0.97 2.05 (0.47–8.88) 0.34
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started on methotrexate, 58 (47.9%) required third line
therapy in the form of one or more biologic agent. Ter-
tiary referral patients were 1.6 times more likely to be
treated with a biologic when compared to primary refer-
ral patients (41.9% vs 26%). This difference was statisti-
cally significant (p = 0.03). Children with an associated
systemic disease were statistically more likely to re-
ceive a biologic than those with idiopathic uveitis
(48% vs 15.2% p = < 0.001). However the rates of vis-
ual impairment were similar in the JIA-U and idio-
pathic uveitis cohorts and so the difference in
treatment may represent a milder disease course of
idiopathic uveitis or the longer median duration of
follow up of the JIA-U cohort. Overall rates of bio-
logic use are higher than previous reports. The rate
of biologic use in the idiopathic uveitis cohort
(15.2%) is slightly lower than reported in Sardar et al.
[24] where 21% of patients required third line ther-
apy. However, the proportion of children with idio-
pathic panuveitis and posterior uveitis was slightly
higher in the French cohort, which may explain the
slightly higher rate of biologic use. In 2007 Sauren-
mann et al. [25] reported that 11% of children with
JIA-U received an anti-TNF agent but over the last
10 years biologics have become more widely available
and accepted practice for refractory JIA-U.
Visual outcomes in this cohort are an improvement
on previously published data. Thorne et al. [10] re-
ported in a population of children with JIA-U rates of
visual impairment of 6/15 or worse (≥0.4 logMAR)
and 6/60 or worse (≥1.0 logMAR) of 0.10/UEY and
0.08/EY respectively. In our study, the incidence rate
of visual impairment in those children with JIA-U
was 0.05/EY (> 0.3logMAR) and 0.02/EY (≥1.0log-
MAR). While JIA-U had a higher incidence rate of
visual impairment compared to idiopathic uveitis, the
difference was not significant. Comparison between
rates of ocular complications within our study popu-
lation and previous published data is outlined in
Table 4. In this study eight children developed bilat-
eral visual impairment > 0.3 logMAR and only one
child had bilateral visual impairment ≥1.0logMAR at
final documented contact.
Uncertainties remain on the optimum time to initi-
ate systemic therapy and the duration of systemic
treatments for children with uveitis as well as the vis-
ual outcomes of those children with uveitis moving
on to adulthood. Evidence for biologic treatments
other than Adalimumab remains limited in childhood
uveitis. A trial of subcutaneous tocilizumab for JIA-U
is currently underway which hopefully will provide
further evidence for the use of IL-6 blockade (APTI-
TUDE) [26]. Biologic agents are expensive and carry
an increased risk of infection and other side effects
[27–30] which needs to be balanced against the po-
tential benefits in reducing sight loss. We also recog-
nise the burden to children and their families
managing frequent hospital appointments, eye drops
and immunosuppression regimes. Even in the absence
of long term complications, uveitis can have emo-
tional and psychological consequences for the child
and family encompassing anxiety, anger and fear of
the future [31].
As a retrospective study we acknowledge certain limi-
tations to the study. The duration of follow up within
the patient cohort was unequal in some cases, and as a
result data is not available for all patients at all time
points. Additionally, in a tertiary centre there may be
overrepresentation of severe cases, and children who
had mild disease may have not had been included as
they are no longer managed by the service. Unfortu-
nately therapy adverse events were not captured in this
study. The era of biologic therapy has brought improve-
ments in visual outcomes for children with uveitis but
Table 4 JIA-U Ocular Outcomes per affected eyes
JIA –U Idiopathic Uveitis/Pars Plantis
Current Study
(n = 91)
Tugal-Tutkun [9]
1996 (n = 100)
Kadayifçilar
[33] 2003
(n = 55)
Kump7
2005
(n = 165)
Current Study
(n = 118)
Tugal-Tutkun9
1996 (n = 88)
Kadayifçilar
[33] 2003
(n = 134)
Kump7
2005
(n = 202)
Cataract 42 (26.3%) 71 (71%) 16 (32.7%) 105 (64%) 17 (14.4%) 33 (37.5%) 41 (30.6%) 60 (29.6%)
Glaucoma 15 (9.4%) 30 (30%) 1 (2%) 33 (20%) 0 2 (2.3%) 7 (5.2%) 29 (14.4%)
Band Keratopathy 27 (16.9%) 66 (66%) 5 (10%) 76 (46%) 9 (7.6%) 16 (18.2%) 13 (9.7%) 24 (11.9%)
Post. Synechiae 40 (25%) – – 96 (58%) 22 (18.6%) – – 49 (24.3%)
Optic Disc Swelling 4 (2.5%) 6 (6%) 1 (2%) 5 (3%) 20 (16.9%) 10 (11.4%) 6 (4.5%) 14 (6.9%)
Hypotony 5 (3.1%) 19 (19%) 3 (5.5%) 17 (10%) 1 (0.8%) 2 (2.3%) 1 (0.7%) 1 (0.5%)
Macular Oedema 7 (4.4%) – – – 13 (11%) – – –
Vitreous Haemorrhage 1 (0.6%) 3 (3%) 0 0 0 8 (5%) 2 (1.5%) 3 (1.5%)
Epiretina Membranel 0 – 1 (2%) 17 (10%) 1 (0.8%) – – 20 (9.9%)
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there is still potential for ongoing improvement in out-
comes in the future.
Improved visual outcomes may be a result of a
combination of factors. New therapies are capable of
controlling inflammation refractory to conventional im-
munosuppressive therapy [20]. However clinical practice
has evolved over the past decade to include robust and
audited JIA uveitis screening standards [32], early treat-
ment and close monitoring of affected children within a
multidisciplinary team. The establishment of a combined
paediatric rheumatology and uveitis clinic with specialist
nurses at the Bristol Eye Hospital has been crucial in
providing timely and effective monitoring and manage-
ment for children with complex uveitis. The implemen-
tation of these practices may have contributed to
improved outcomes.
Conclusion
This study has demonstrated an encouraging im-
provement in the rate of ocular complications and
visual impairment in children with non-infectious
uveitis when compared to previous publications. Not-
ably, the rate of biologic use was high (34.9%),
reflecting their increasing importance in modern
immunomodulation. Visual outcomes between the
JIA-U and idiopathic uveitis cohorts were not signifi-
cant. Cataract development was the most common
ocular complication within the cohort.
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